# EDGAR Filing Document

**Accession Number:** 0000728387
**File Stem:** 0000728387-25-000006
**Filing Date:** 2025-9
**Character Count:** 8848
**Document Hash:** afa1705accdda1316819c7dc7023d5f0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000728387-25-000006.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0000728387-25-000006

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 74

**CONFORMED PERIOD OF REPORT**: 20250902

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250902

**DATE AS OF CHANGE**: 20250902

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Perspective Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000728387
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411458152
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33407
- **FILM NUMBER:** 251282913

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-676-0900

**MAIL ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Isoray, Inc.
- **DATE OF NAME CHANGE:** 20181231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IsoRay, Inc.
- **DATE OF NAME CHANGE:** 20050805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY PARK PICTURES CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** September 2, 2025<br>

------

Perspective Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-33407 | 41-1458152 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| c/o Perspective Therapeutics, Inc.<br>2401 Elliott Avenue<br>Suite 320 |  |  |
| Seattle**,** Washington |  | 98121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (206) 676-0900<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value | CATX | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 8.01 Other Events.
On September 2, 2025, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 99.1 | [<u>Corporate Presentation</u>](catx-ex99_1.htm). |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **PERSPECTIVE THERAPEUTICS, INC.** |
| Date: | September 2, 2025 | By:  | /s/ Juan Graham |
|  |  |  | Juan Graham<br>Chief Financial Officer |

---

------

## Exhibit 99.1

![Slide 1](catx-ex99_1s1.jpg)

Corporate Presentation

------

![Slide 2](catx-ex99_1s2.jpg)

------

![Slide 3](catx-ex99_1s3.jpg)

Developing the Next Generation of Targeted Therapies

------

![Slide 4](catx-ex99_1s4.jpg)

Higher Potency Payloads with Cancer-Specific Targeting

------

![Slide 5](catx-ex99_1s5.jpg)

------

![Slide 6](catx-ex99_1s6.jpg)

Radiopharmaceutical Therapy Poised to Revolutionize Oncology TreatmentPerspective's pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

------

![Slide 7](catx-ex99_1s7.jpg)

------

![Slide 8](catx-ex99_1s8.jpg)

Perspective's Innovative Platform

------

![Slide 9](catx-ex99_1s9.jpg)

Perspective's Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window

------

![Slide 10](catx-ex99_1s10.jpg)

Perspective's Proprietary Chelator Has Been Optimized for Lead-Based RPTs

------

![Slide 11](catx-ex99_1s11.jpg)

------

![Slide 12](catx-ex99_1s12.jpg)

------

![Slide 13](catx-ex99_1s13.jpg)

Proposed Mechanism of Action for 212Pb

------

![Slide 14](catx-ex99_1s14.jpg)

Rationale for Synergy with Immune Checkpoint Inhibitors

------

![Slide 15](catx-ex99_1s15.jpg)

------

![Slide 16](catx-ex99_1s16.jpg)

Supply Chain and Manufacturing Infrastructure

------

![Slide 17](catx-ex99_1s17.jpg)

On-Demand Order Fulfillment at Regional Sites to Deliver Finished Products

------

![Slide 18](catx-ex99_1s18.jpg)

------

![Slide 19](catx-ex99_1s19.jpg)

Neuroendocrine Tumors: VMT-⍺-NET

------

![Slide 20](catx-ex99_1s20.jpg)

------

![Slide 21](catx-ex99_1s21.jpg)

------

![Slide 22](catx-ex99_1s22.jpg)

------

![Slide 23](catx-ex99_1s23.jpg)

Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors

------

![Slide 24](catx-ex99_1s24.jpg)

Anti-Tumor Activity

------

![Slide 25](catx-ex99_1s25.jpg)

[212Pb]VMT-α-NET Was Well Tolerated

------

![Slide 26](catx-ex99_1s26.jpg)

Mild and Generally Transient Blood Creatinine Increase

------

![Slide 27](catx-ex99_1s27.jpg)

------

![Slide 28](catx-ex99_1s28.jpg)

Patient (103-105) with Confirmed PR After [212Pb]VMT-α-NET

------

![Slide 29](catx-ex99_1s29.jpg)

Melanoma Program: VMT01/02

------

![Slide 30](catx-ex99_1s30.jpg)

------

![Slide 31](catx-ex99_1s31.jpg)

------

![Slide 32](catx-ex99_1s32.jpg)

------

![Slide 33](catx-ex99_1s33.jpg)

------

![Slide 34](catx-ex99_1s34.jpg)

Trial Design: [212Pb]VMT01 Phase 1/2a For Metastatic Melanoma

------

![Slide 35](catx-ex99_1s35.jpg)

------

![Slide 36](catx-ex99_1s36.jpg)

Treatment Emergent Adverse Events (all grades, occurring in ≥ 2 patients)

------

![Slide 37](catx-ex99_1s37.jpg)

------

![Slide 38](catx-ex99_1s38.jpg)

------

![Slide 39](catx-ex99_1s39.jpg)

------

![Slide 40](catx-ex99_1s40.jpg)

------

![Slide 41](catx-ex99_1s41.jpg)

------

![Slide 42](catx-ex99_1s42.jpg)

PSV359 is Active Against FAP-α Expression on Tumor and on Stroma

------

![Slide 43](catx-ex99_1s43.jpg)

------

![Slide 44](catx-ex99_1s44.jpg)

------

![Slide 45](catx-ex99_1s45.jpg)

Trial Design: [212Pb]PSV359 Phase 1/2a Trial

------

![Slide 46](catx-ex99_1s46.jpg)

------

![Slide 47](catx-ex99_1s47.jpg)

General Corporate Information

------

![Slide 48](catx-ex99_1s48.jpg)

------

![Slide 49](catx-ex99_1s49.jpg)

------

![Slide 50](catx-ex99_1s50.jpg)

------

![Slide 51](catx-ex99_1s51.jpg)

------

![Slide 52](catx-ex99_1s52.jpg)

Abbreviations

------

![Slide 53](catx-ex99_1s53.jpg)

APPENDIX

------

![Slide 54](catx-ex99_1s54.jpg)

------

![Slide 55](catx-ex99_1s55.jpg)

NETs Trials

------

![Slide 56](catx-ex99_1s56.jpg)

Refractory Metastatic Melanoma Trials

------

![Slide 57](catx-ex99_1s57.jpg)

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

------

![Slide 58](catx-ex99_1s58.jpg)

------

![Slide 59](catx-ex99_1s59.jpg)

------

![Slide 60](catx-ex99_1s60.jpg)

------

![Slide 61](catx-ex99_1s61.jpg)

------

![Slide 62](catx-ex99_1s62.jpg)

------

![Slide 63](catx-ex99_1s63.jpg)

Perspective's Pre-Targeting Platform